Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]
Immunovant, Inc. (IMVT)
Company Research
Source: Seeking Alpha
Matthew Gline - CEO & Director Benjamin Zimmer Richard Pulik - Chief Financial Officer Frank Torti Eric Venker - President & CEO of Immunovant Carlos Sanmarco Conference Call Participants Corinne Jenkins - Goldman Sachs Group, Inc., Research Division David Risinger - Leerink Partners LLC, Research Division Yaron Werber - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Dr. Mark Lupo Yasmeen Rahimi - Piper Sandler & Co., Research Division Drew Fromkin Carlos Sanmarco Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Lindsay Androski - Arbutus Biopharma Corporation Samantha Lynn Semenkow - Citigroup Inc. Exchange Research Hanxing Gao - Guggenheim Securities, LLC, Research Division Conversation Keyur Parekh Good morning, and thank you to those joining us in person on this cold New York morning. An equally warm welcome to those joining us virtually. My name is Keyur Parekh, and I head Investor Relation
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]Seeking Alpha
- Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Pricing of $550 Million Common Stock FinancingGlobeNewswire
- Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Analyst Actions
- 9/30/25 - JP Morgan
IMVT
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form 4
- 12/12/25 - Form 8-K
- IMVT's page on the SEC website